Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 22, 2024
Reporting Period: Event date of May 22, 2024
This filing reports a corporate governance change approved by the Board of Directors. The company is an emerging growth company incorporated in Nevada.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is limited to reporting a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
Change in Voting Standard: On May 22, 2024, the Board of Directors approved an amendment to the Company's bylaws. The voting standard for the election of directors was changed from a plurality standard to a majority voting standard. This amendment became effective immediately on May 22, 2024.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The document focuses solely on the bylaw amendment.
Key Facts for Investor Verification
- Verify the effective date of the majority voting standard for director elections (May 22, 2024).
- Review the full text of the First Amendment to the Bylaws attached as Exhibit 3.1 for specific procedural details.
- Confirm the company's status as an emerging growth company.